Disarming cellular alarm systems-manipulation of stress-induced NKG2D ligands by human herpesviruses

Frontiers in Immunology

Volumn 8, Issue APR, 2017, Pages

  Schmiedel, Dominik ^a   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Coevolution; Host pathogen interaction; Immune evasion; NKG2D ligands; NKG2D,herpesvirus; Stress induced ligands

Indexed keywords

LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D;

ALLELE; CELL MANIPULATION; CELLULAR STRESS SIGNAL; COEVOLUTION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION REGULATION; HERPES VIRUS INFECTION; HERPESVIRIDAE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; KAPOSI SARCOMA; NATURAL KILLER CELL; NONHUMAN; ROSEOLOVIRUS; SHORT SURVEY; VARICELLA ZOSTER VIRUS; VIRAL GENETICS;

EID: 85018425782     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00390     Document Type: Short Survey

References (91)

1. Wertheim JO, Smith MD, Smith DM, Scheffler K, Kosakovsky Pond SL. Evolutionary origins of human herpes simplex viruses 1 and 2. Mol Biol Evol (2014) 31:2356-64. doi:10.1093/molbev/msu185
2. Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press (2007)
3. Grinde B. Herpesviruses: latency and reactivation-viral strategies and host response. J Oral Microbiol (2013) 5. doi:10.3402/jom.v5i0.22766
4. Cohen JI. Epstein-Barr virus infection. N Engl J Med (2000) 343:481-92. doi:10.1056/NEJM200008173430707
5. Kowitdamrong E, Pancharoen C, Thammaborvorn R, Bhattarakosol P. The prevalence of varicella-zoster virus infection in normal healthy individuals aged above 6 months. J Med Assoc Thai (2005) 88(Suppl 4):S7-11
6. Wald A, Corey L. Persistence in the population: epidemiology, transmission. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press (2007)
7. Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press (2007)
8. Emery VC, Clark DA. HHV-6A, 6B, and 7: persistence in the population, epidemiology and transmission. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press (2007)
9. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health (1998) 3:886-90. doi:10.1046/j.1365-3156.1998.00316.x
10. Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine (2001) 20:121-4. doi:10.1016/S0264-410X(01)00276-6
11. Hofscheier A, Ponciano A, Bonzheim I, Adam P, Lome-Maldonado C, Vela T, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol (2011) 24:1046-54. doi:10.1038/modpathol.2011.62
12. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis (2013) 208:1286-93. doi:10.1093/infdis/jit321
13. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev (2013) 26:86-102. doi:10.1128/CMR.00062-12
14. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med (2010) 267:483-501. doi:10.1111/j.1365-2796.2010.02220.x
15. Kinchington PR, Leger AJ, Guedon JM, Hendricks RL. Herpes simplex virus and varicella zoster virus, the house guests who never leave. Herpesviridae (2012) 3:5. doi:10.1186/2042-4280-3-5
16. Hu Z, Usherwood EJ. Immune escape of gamma-herpesviruses from adaptive immunity. Rev Med Virol (2014) 24:365-78. doi:10.1002/rmv.1791
17. Wang FZ, Pellett PE. HHV-6A, 6B, and 7: immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press (2007)
18. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology (2013) 2:e26097. doi:10.4161/onci.26097
19. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 28:571-80. doi:10.1016/j.immuni.2008.02.016
20. Guerra N, Pestal K, Juarez T, Beck J, Tkach K, Wang L, et al. A selective role of NKG2D in inflammatory and autoimmune diseases. Clin Immunol (2013) 149:432-9. doi:10.1016/j.clim.2013.09.003
21. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect (2002) 4:1545-58. doi:10.1016/S1286-4579(02)00038-2
22. Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol (2013) 132:515-525; quiz 526. doi:10.1016/j.jaci.2013.07.020
23. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 3:781-90. doi:10.1038/nri1199
24. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene (2008) 27:5944-58. doi:10.1038/onc.2008.272
25. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol (2008) 29:397-403. doi:10.1016/j.it.2008.04.007
26. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 93:12445-50. doi:10.1073/pnas.93.22.12445
27. Lanier LL. NK cell receptors. Annu Rev Immunol (1998) 16:359-93. doi:10.1146/annurev.immunol.16.1.359
28. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 25:331-42. doi:10.1016/j.immuni.2006.06.013
29. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol (2007) 7:737-44. doi:10.1038/nri2144
30. Fernandez-Messina L, Reyburn HT, Vales-Gomez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol (2012) 3:299. doi:10.3389/fimmu.2012.00299
31. Choy MK, Phipps ME. MICA polymorphism: biology and importance in immunity and disease. Trends Mol Med (2010) 16:97-106. doi:10.1016/j.molmed.2010.01.002
32. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 14:123-33. doi:10.1016/S1074-7613(01)00095-4
33. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol (2001) 2:443-51. doi:10.1038/87757
34. Holmes MA, Li P, Petersdorf EW, Strong RK. Structural studies of allelic diversity of the MHC class I homolog MIC-B, a stress-inducible ligand for the activating immunoreceptor NKG2D. J Immunol (2002) 169:1395-400. doi:10.4049/jimmunol.169.3.1395
35. Nachmani D, Gutschner T, Reches A, Diederichs S, Mandelboim O. RNA-binding proteins regulate the expression of the immune activating ligand MICB. Nat Commun (2014) 5:4186. doi:10.1038/ncomms5186
36. Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, et al. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife (2015) 4:e08474. doi:10.7554/eLife.08474
37. Schmiedel D, Tai J, Yamin R, Berhani O, Bauman Y, Mandelboim O. The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB. Elife (2016) 5:e13426. doi:10.7554/eLife.13426
38. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol (2008) 9:1065-73. doi:10.1038/ni.1642
39. Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, et al. miR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res (2012) 72:5463-72. doi:10.1158/0008-5472.CAN-11-2671
40. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet (2001) 357:1513-8. doi:10.1016/S0140-6736(00)04638-9
41. Siegel MA. Diagnosis and management of recurrent herpes simplex infections. J Am Dent Assoc (2002) 133:1245-9. doi:10.14219/jada.archive.2002.0366
42. Schepis D, D'Amato M, Studahl M, Bergstrom T, Karre K, Berg L. Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol (2009) 69:429-36. doi:10.1111/j.1365-3083.2009.02241.x
43. Campbell TM, McSharry BP, Steain M, Slobedman B, Abendroth A. Varicella-zoster virus and herpes simplex virus 1 differentially modulate NKG2D ligand expression during productive infection. J Virol (2015) 89:7932-43. doi:10.1128/JVI.00292-15
44. Enk J, Levi A, Weisblum Y, Yamin R, Charpak-Amikam Y, Wolf DG, et al. HSV1 microRNA modulation of GPI anchoring and downstream immune evasion. Cell Rep (2016) 17:949-56. doi:10.1016/j.celrep.2016.09.077
45. Ohishi K, Inoue N, Kinoshita T. PIG-S and PIG-T, essential for GPI anchor attachment to proteins, form a complex with GAA1 and GPI8. EMBO J (2001) 20:4088-98. doi:10.1093/emboj/20.15.4088
46. Kinoshita T, Fujita M, Maeda Y. Biosynthesis, remodelling and functions of mammalian GPI-anchored proteins: recent progress. J Biochem (2008) 144:287-94. doi:10.1093/jb/mvn090
47. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol (2009) 8:731-40. doi:10.1016/S1474-4422(09)70134-6
48. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin (2008) 26:675-697, viii. doi:10.1016/j.ncl.2008.03.011
49. Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 118:45-58. doi:10.7326/0003-4819-118-1-199301010-00009
50. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol (2000) 71:108-17
51. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med (2007) 9:1-24. doi:10.1017/S1462399407000312
52. Pappworth IY, Wang EC, Rowe M. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol (2007) 81:474-82. doi:10.1128/JVI.01777-06
53. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe (2009) 5:376-85. doi:10.1016/j.chom.2009.03.003
54. Song H, Park H, Kim J, Park G, Kim YS, Kim SM, et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett (2011) 136:187-93. doi:10.1016/j.imlet.2011.01.009
55. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol (2015) 235:288-97. doi:10.1002/path.4437
56. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, et al. Host immune system gene targeting by a viral miRNA. Science (2007) 317:376-81. doi:10.1126/science.1140956
57. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, et al. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol (2001) 31:1428-37. doi:10.1002/1521-4141(200105)31:5<1428:AID-IMMU1428>3.0.CO;2-4
58. Rolle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Soderberg-Naucler C, Cosman D, et al. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol (2003) 171:902-8. doi:10.4049/jimmunol.171.2.902
59. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med (2003) 197:1427-39. doi:10.1084/jem.20022059
60. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol (2003) 170:4196-200. doi:10.4049/jimmunol.170.8.4196
61. Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale J. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol (2009) 39:3207-16. doi:10.1002/eji.200939502
62. Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol (2009) 83:12345-54. doi:10.1128/JVI.01175-09
63. Bennett NJ, Ashiru O, Morgan FJ, Pang Y, Okecha G, Eagle RA, et al. Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J Immunol (2010) 185:1093-102. doi:10.4049/jimmunol.1000789
64. Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, et al. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog (2014) 10:e1004058. doi:10.1371/journal.ppat.1004058
65. Zhang Y, Lazaro AM, Lavingia B, Stastny P. Typing for all known MICA alleles by group-specific PCR and SSOP. Hum Immunol (2001) 62:620-31. doi:10.1016/S0198-8859(01)00241-5
66. Petersdorf EW, Shuler KB, Longton GM, Spies T, Hansen JA. Population study of allelic diversity in the human MHC class I-related MIC-A gene. Immunogenetics (1999) 49:605-12. doi:10.1007/s002510050655
67. Vales-Gomez M. The impact of glycosyl-phosphatidyl-inositol anchored MICA alleles on novel NKG2D-based therapies. Front Immunol (2015) 6:193. doi:10.3389/fimmu.2015.00193
68. Seidel E, Le VT, Bar-On Y, Tsukerman P, Enk J, Yamin R, et al. Dynamic co-evolution of host and pathogen: HCMV downregulates the prevalent allele MICA *008 to escape elimination by NK cells. Cell Rep (2015) 10:968-82. doi:10.1016/j.celrep.2015.01.029
69. Kondo K, Yamanishi K. HHV-6A, 6B, and 7: molecular basis of latency and reactivation. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press (2007)
70. Ongradi J, Ablashi DV, Yoshikawa T, Stercz B, Ogata M. Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals. J Neurovirol (2017) 23(1):1-19. doi:10.1007/s13365-016-0473-0
71. Schmiedel D, Tai J, Levi-Schaffer F, Dovrat S, Mandelboim O. Human herpesvirus 6B downregulates expression of activating ligands during lytic infection to escape elimination by natural killer cells. J Virol (2016) 90:9608-17. doi:10.1128/JVI.01164-16
72. Schneider CL, Hudson AW. The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog (2011) 7:e1002362. doi:10.1371/journal.ppat.1002362
73. Viejo-Borbolla A, Schulz TF. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev (2003) 5:222-9
74. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 332:1186-91. doi:10.1056/NEJM199505043321802
75. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, et al. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A (2008) 105:1656-61. doi:10.1073/pnas.0707883105
76. Stern-Ginossar N, Weisburd B, Michalski A, Le VT, Hein MY, Huang SX, et al. Decoding human cytomegalovirus. Science (2012) 338:1088-93. doi:10.1126/science.1227919
77. Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, et al. KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog (2014) 10:e1003847. doi:10.1371/journal.ppat.1003847
78. Tycowski KT, Guo YE, Lee N, Moss WN, Vallery TK, Xie M, et al. Viral noncoding RNAs: more surprises. Genes Dev (2015) 29:567-84. doi:10.1101/gad.259077.115
79. Zhang Q, Jeang KT. Long non-coding RNAs (lncRNAs) and viral infections. Biomed Pharmacother (2013) 3:34-42. doi:10.1016/j.biomed.2013.01.001
80. Samarakoon A, Chu H, Malarkannan S. Murine NKG2D ligands: "double, double toil and trouble". Mol Immunol (2009) 46:1011-9. doi:10.1016/j.molimm.2008.09.035
81. Meyer A, Carapito R, Ott L, Radosavljevic M, Georgel P, Adams EJ, et al. High diversity of MIC genes in non-human primates. Immunogenetics (2014) 66:581-7. doi:10.1007/s00251-014-0791-4
82. Anzai T, Shiina T, Kimura N, Yanagiya K, Kohara S, Shigenari A, et al. Comparative sequencing of human and chimpanzee MHC class I regions unveils insertions/deletions as the major path to genomic divergence. Proc Natl Acad Sci U S A (2003) 100:7708-13. doi:10.1073/pnas.1230533100
83. de Groot NG, Garcia CA, Verschoor EJ, Doxiadis GG, Marsh SG, Otting N, et al. Reduced MIC gene repertoire variation in West African chimpanzees as compared to humans. Mol Biol Evol (2005) 22:1375-85. doi:10.1093/molbev/msi127
84. Spreu J, Stehle T, Steinle A. Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains. J Immunol (2006) 177:3143-9. doi:10.4049/jimmunol.177.5.3143
85. Klumkrathok K, Jumnainsong A, Leelayuwat C. Allelic MHC class I chain related B (MICB) molecules affect the binding to the human cytomegalovirus (HCMV) unique long 16 (UL16) protein: implications for immune surveillance. J Microbiol (2013) 51:241-6. doi:10.1007/s12275-013-2514-1
86. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, et al. Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci U S A (2015) 112:E4120-8. doi:10.1073/pnas.1501880112
87. Sijmons S, Thys K, Mbong Ngwese M, Van Damme E, Dvorak J, Van Loock M, et al. High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. J Virol (2015) 89:7673-95. doi:10.1128/JVI.00578-15
88. Komatsu-Wakui M, Tokunaga K, Ishikawa Y, Kashiwase K, Moriyama S, Tsuchiya N, et al. MIC-A polymorphism in Japanese and a MIC-A-MIC-B null haplotype. Immunogenetics (1999) 49:620-8. doi:10.1007/s002510050658
89. Ota M, Bahram S, Katsuyama Y, Saito S, Nose Y, Sada M, et al. On the MICA deleted-MICB null, HLA-B*4801 haplotype. Tissue Antigens (2000) 56:268-71. doi:10.1034/j.1399-0039.2000.560309.x
90. Komatsu-Wakui M, Tokunaga K, Ishikawa Y, Leelayuwat C, Kashiwase K, Tanaka H, et al. Wide distribution of the MICA-MICB null haplotype in East Asians. Tissue Antigens (2001) 57:1-8. doi:10.1034/j.1399-0039.2001.057001001.x
91. Aida K, Russomando G, Kikuchi M, Candia N, Franco L, Almiron M, et al. High frequency of MIC null haplotype (HLA-B48-MICA-del-MICB*0107 N) in the Angaite Amerindian community in Paraguay. Immunogenetics (2002) 54:439-41. doi:10.1007/s00251-002-0485-1